Stay updated on RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial
Sign up to get notified when there's something new on the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page.

Latest updates to the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page
- Check3 days agoChange DetectedThe Locations section was expanded to include Arizona, California, Colorado, Illinois, Indiana, Kentucky, Massachusetts, Nevada, North Carolina, North Dakota, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, and Virginia with revision v3.3.3, while the HHS Vulnerability Disclosure and the previously listed state locations were removed.SummaryDifference2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

- Check39 days agoChange DetectedRemoved the government funding status notice from the page; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check54 days agoChange DetectedThe updated page shows minor visual/layout adjustments with no changes to study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check82 days agoChange DetectedAdded a government operating-status notice and updated version to v3.2.0; removed the previous v3.1.0 reference.SummaryDifference5%

- Check89 days agoChange DetectedAdded a new page revision tag (v3.1.0) and removed several MedlinePlus topics, simplifying the topic scope. No core content or time-sensitive information appears updated.SummaryDifference0.8%

Stay in the know with updates to RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page.